Christoph Feest, PhD

@christoph-feest.bsky.social

Democratising access to AI.

And if they work, these drugs will hit the market in the 2030s. That's how long clinical development takes. It is a painful lesson for the first wave of AI-driven biotech (Benevolent AI, Recursion & Exscientia, Owkin...) investors. DD is a long game.

Financial Times@financialtimes.com · 2y ago

Google's Demis Hassabis, who founded Isomorphic Labs, told the FT it was looking at 'all the big disease areas' including oncology and neurodegeneration. www.ft.com/content/41b5...

Chuffed about the expanding footprint @neuripsconf.bsky.social of researchers from our directly funded labs and consulting teams. Enjoy Vancouver, everyone!

Helmholtz AI@helmholtzai.bsky.social · 2y ago

Gooooood morning, Vancouver! ☀️ It's the first day of the @neuripsconf.bsky.social 2024, and we are excited to share the strong presence of Helmholtz AI researchers in Canada for the next 5 days - find the abstracts of work to be showcased below: www.helmholtz.ai/detail/helmh...

Enjoyed this Babbage podcast @economist.com about the Human Cell Atlas on the commute. A very accessible update on this truly global effort pairing biology, AI and medicine. "They'll have a draft next year." 😀 Why scientists are building an atlas of the human body www.economist.com/podcasts/202...

Why scientists are building an atlas of the human body

Our podcast on science and technology. We meet the scientists behind a global project that promises to transform scientists’ understanding of organ development and disease

economist.com